A global champion of ‘the big puzzle’ — biochemistry
After more than three decades as a biochemist, Alexandra Newton remains on a quest to figure out how molecules interact and work with each other. Specifically, she wants to understand the mechanisms of target molecules such as enzymes in maintaining human health and manifestation of disease.

"For the development of effective therapies, in-depth understanding of the biochemical mechanisms is critical," she said. "Biochemistry is like a big puzzle, where you are finding and piecing together different pieces. A new piece might take you into new directions. It's like I'm the detective working toward solving a problem, considering all the clues available. There is never a dull moment."
Now a professor of pharmacology at the University of California, San Diego, Newton has lived on three continents and completed her education in seven countries. Her father was English, and her mother is from Cyprus. Born in Cape Town, South Africa, she grew up in Canada, Greece, France and other countries. She speaks Greek, English, French and German.
These factors, along with her dedication to biochemistry, helped Newton grow as a scientist and become a mentor to students across the globe. Now they will serve her as the third woman president of . The union unites biochemists and molecular biologists in 79 countries, promoting research and education throughout the world. The 91Ӱ and Molecular Biology is a member of the IUBMB, and Newton will be the first woman 91Ӱmember to lead the IUBMB.
Becoming a scientist
As a little girl, Newton was intensely curiosity about science. "I began experimenting very young," she said.
For her first experiment, instead of sending a baby molar to the tooth fairy, she measured the tooth's diameter before and after submerging it in soft drinks to determine the sodas' effect on dental decay. "My parents told me that soft drinks are not good for you, but I wanted to find out myself," she said. "So, I do not drink soft drinks."
During her undergraduate years at in Vancouver, Canada, her teachers nurtured her interest in biochemistry. When she was a grad student at , membrane biochemistry sparked her interest. She did a postdoc in .'s lab at the University of California, studying how lipids modulate the activity of , or PKC, an enzyme involved in metabolic regulation, immune signaling and cell proliferation. has helped researchers understand the mechanism and regulation of PKC.

As a distinguished professor of pharmacology at UC San Diego and co-director of the molecular pharmacology track in the biomedical sciences graduate program, Newton is an advocate for basic biochemistry research. She is also director of Cell Signaling San Diego, a new center that brings together local experts in the field. She continues to explore the molecular mechanisms of cell signaling and their deregulation in diseases, with emphasis on her favorite molecule, PKC, and the phosphatase PHLPP.
Newton's team reversed a 30-year paradigm when they reported their finding that PKC suppresses, rather than promotes, tumors. For decades, attempts to develop drugs that inhibit PKC as a part of cancer treatment had failed, she said. "Our study showed that we needed to develop anti-cancer drugs that would boost PKC activity."
Newton uses PKC as an example of the importance of understanding the biochemistry of a target before developing therapies. Her lab has found that PKC's activity is enhanced in neurodegenerative diseases: In Alzheimer's, a few atoms' difference in one isozyme of PKC increases its activity, which, in a mouse model, is enough to cause cognitive decline.

An international vision
Newton has been IUBMB's president-elect since July 2018; she will become president in July 2021, and past president in 2024 — a nine-year commitment. Her vision as president is to foster scientific alliances that are inclusive about geographical and gender diversity. The union already provides opportunities to scientists and students from developing countries in programs such as Promoting Research Opportunities for Latin American Biochemists, or , a joint initiative with the 91Ӱand the Pan-91Ӱ and Molecular Biology that brings Latin American scientists to work in North American labs.
The IUBMB executive committee has an equal number of men and women, and Newton views the organization as a model for gender diversity. "It is tricky for our virtual executive committee meetings at the moment, which span 18 time zones," she said, "but our leadership team has members from all over the world."

Representation of women in science has improved since Newton started as a graduate student; her Stanford class in chemistry included two women. Later, she was the only woman among 43 faculty members in the chemistry department. She is proud that her department at UC San Diego has equal numbers of men and women researchers, but she realizes the difficulties women still face in the sciences, and she works to find solutions that will promote inclusion and diversity in the field.
"I always tell anyone who is starting a career in science, focus on the positives," she said. "Follow your passion and love what you are doing to overcome all the negatives."
Other challenges have been subsumed by the COVID-19 pandemic, but Newton believes now is the time for scientists worldwide to come together. She supports communicating science across boundaries in the form of virtual conferences and webinars, seeing the new necessity as an opportunity: "This pandemic has also allowed me to open my courses and lectures for students from different countries."
She noted that the IUBMB now offers virtual conference fellowships, allowing students from all over the world to attend meetings.
Newton is unfazed at holding a world leadership role.
"I see a silver lining for the unusual year of 2020," she said. "This pandemic has brought together scientists around the globe. Physical boundaries did not stop scientists from trying to work together. Virtual conferences have not only helped provide access to a larger community but also bought out the innovative ways to communicate science."
Enjoy reading 91ӰToday?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91ӰToday
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles

Fliesler wins scientific and ethical awards
He is being honored by the University at Buffalo and the American Oil Chemists' Society for his scientific achievements and ethical integrity.

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

91Ӱmembers recognized as Allen investigators
Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.

AI can be an asset, 91Ӱeducators say
Pedagogy experts share how they use artificial intelligence to save time, increase accessibility and prepare students for a changing world.

91Ӱundergraduate education programs foster tomorrow’s scientific minds
Learn how the society empowers educators and the next generation of scientists through community as well as accreditation and professional development programs that support evidence-based teaching and inclusive pedagogy.